The article discusses Tazbentetol, a novel agent targeting synaptic regeneration for the treatment of schizophrenia, representing a new mechanism of action in psychiatric drug development.
XTL Therapeutics plans to acquire Psyga to consolidate a portfolio of seven Phase 2a psychedelic trials, signaling continued industry investment in psychotropic drug development.
The MHRA has issued a recall for a popular antidepressant after patients discovered the bottle contained the wrong medication, highlighting a critical patient safety and prescribing error.
Validation of the Tardive Dyskinesia Impact Scale (TDIS) provides a patient-reported outcome measure to assess the functional and socioemotional burden of TD, complementing clinician ratings in the context of VMAT2 inhibitor treatment.
The Tardive Dyskinesia Impact Scale (TDIS) provides a patient-reported outcome measure that captures socioemotional benefits of VMAT2 inhibitors like valbenazine beyond traditional motor symptom scales, informing clinical assessment of treatment efficacy.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Feb 25 – Apr 29)
- Verify the specific batch numbers of sertraline prescriptions against current FDA and MHRA recall alerts to prevent dispensing errors involving mislabeled packaging.
- Consider prescribing lumateperone for maintenance therapy in schizophrenia to prevent relapse, as it now holds a specific FDA indication beyond acute treatment.
- Utilize the CYPRI tool to prioritize patients for CYP2D6/CYP2C19 pharmacogenetic testing, thereby improving the cost-effectiveness and clinical utility of psychopharmacogenomics.
- Monitor patients on sertraline and montelukast closely for emerging suicidal ideation, particularly in youth populations, given recent FAERS safety signals.
- Advise clinicians to integrate psychotherapy with medication for opioid use disorder, as multimodal care yields significantly higher remission rates than either modality alone.
- Use the Tardive Dyskinesia Impact Scale (TDIS) to assess patient-reported socioemotional benefits when evaluating treatment efficacy with VMAT2 inhibitors like valbenazine.
- Exercise caution when treating mixed overdoses of diphenhydramine and dextromethorphan, as delayed serotonin toxicity can occur and requires prolonged monitoring.
- Consider extended-release buprenorphine as a safe and effective option for treating opioid use disorder in pregnant individuals based on recent clinical trial data.
- Advocate for reduced antipsychotic polypharmacy and increased clozapine utilization in schizophrenia management, particularly in regions where polypharmacy rates are high.
- Evaluate the potential for culturally adapted digital CBT as a safe adjunct to pharmacotherapy for reducing pathological worry in patients with generalized anxiety disorder.
Drug Development 3
Bristol-Myers Squibb's novel schizophrenia treatment has encountered early setbacks, signaling potential challenges for this new therapeutic approach in the treatment of schizophrenia.
A pilot study investigates the use of psilocybin for post-treatment Lyme disease, representing early-phase research into a psychedelic's potential off-label application for a condition with significant neuropsychiatric comorbidities.
Teva acquires Emalex Biosciences for $700M to advance ecopipam, a D1 antagonist targeting Tourette syndrome, positioning it as a later-line therapy with a potentially improved safety profile compared to current antipsychotic and alpha-2 agonist standards.
Policy & Regulation 4
A retrospective FAERS analysis identifies age-specific suicide risk signals for CNS medications, highlighting montelukast and sertraline in youth and hydrocodone/acetaminophen in the elderly.
The FDA has updated the labeling for the antipsychotic Caplyta (lumateperone) to include a new indication for preventing relapse in patients with schizophrenia.
The FDA has approved lumateperone for the prevention of relapse in adults with schizophrenia, expanding its therapeutic indication beyond acute treatment.
The FDA has approved Janssen's Caplyta (lumateperone) for the treatment of schizophrenia, marking a new therapeutic option for managing the condition.
Diagnosis & Treatment 3
This retrospective study confirms that shorter duration of untreated psychosis predicts better short-term symptom improvement in first-episode schizophrenia, reinforcing the clinical imperative for early detection and intervention.
A study reveals that 50% of older dementia patients remain on psychotropic medications one year after initiation, highlighting a significant prescribing pattern and potential need for deprescribing.
Ketamine therapy is being utilized as a treatment option for Israeli combat veterans with PTSD, highlighting its clinical application in this specific population.
Pharmacogenomics 1
The CYPRI tool helps psychiatrists prioritize patients for CYP2D6/CYP2C19 pharmacogenetic testing by estimating the likelihood of actionable results, potentially improving cost-effectiveness in psychopharmacology.
Clinical Pearl 5
A case report demonstrates that long-acting injectable paliperidone effectively reduced post-traumatic aggression in a pediatric TBI patient with poor oral adherence, highlighting its potential utility for behavioral dysregulation when standard oral therapies fail.
This case report highlights the risk of delayed serotonin toxicity in mixed overdoses of diphenhydramine and dextromethorphan, emphasizing the need to monitor for evolving toxidromes in intentional ingestions.
A national multi-organization analysis demonstrates that combining MOUD (buprenorphine or methadone) with psychotherapy yields significantly higher remission rates for opioid use disorder than either modality alone, supporting integrated multimodal care.
Clinical trial data support the safety and efficacy of extended-release buprenorphine for treating opioid use disorder in pregnant individuals.
A clinical trial comparing SSRIs to acupuncture for anxiety and depression, providing evidence on the relative efficacy of pharmacotherapy versus a non-pharmacologic intervention.
Journal Article 1
A meta-analysis reveals that antipsychotic polypharmacy affects 50% of schizophrenia patients in MENAT/EMRO regions, prompting recommendations to reduce polypharmacy and increase clozapine utilization.
Digital Health 2
The PETRUSHKA tool, developed by Andrea Cipriani, improves antidepressant persistence in patients with major depressive disorder, offering a practical strategy to enhance medication adherence.
A pilot study suggests that a culturally adapted digital CBT program can be safely used as an adjunct to pharmacotherapy to enhance reductions in pathological worry for patients with generalized anxiety disorder.